Zobrazeno 1 - 10 of 41 pro vyhledávání: '"N W, Peacock"'
1
Abstract PS11-29: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic triple-negative breast cancer (TNBC)
Autor: John D. Hainsworth, Howard A. Burris, Denise A. Yardley, N. W. Peacock, Kommor M, Robyn R. Young, Mythili Shastry, Davey B. Daniel, Jose E. Najera, Andrea Silber, Kerin B. Adelson
Publikováno v: Cancer Research. 81:PS11-29
Background: Treatment options for TNBC are limited by the lack of estrogen and progesterone receptors as well as the absence of HER2 overexpression. AR is present in all breast cancer subtypes and up to 40% of TNBC have AR overexpression (AR+). Thus
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8a41fc25291b2d6a4adbfd99c577d54e
https://doi.org/10.1158/1538-7445.sabcs20-ps11-29
Zobrazit plný text záznamu
2
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)
Autor: L Finney, Robyn R. Young, Denise A. Yardley, Andrea Silber, Kerin B. Adelson, Davey B. Daniel, Howard A. Burris, John D. Hainsworth, N. W. Peacock, Susan J. Hoekstra, Mythili Shastry, Jose E. Najera
Publikováno v: Clinical breast cancer. 22(3)
Background : AR is a targetable pathway with AR modulation inhibiting estrogen- and androgen-mediated cell proliferation. Orteronel is an oral, selective, nonsteroidal inhibitor of 17, 20-lyase, a key enzyme in androgen biosynthesis. This study evalu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a5ecc47471f18b6b7ff466b9aac154e
https://pubmed.ncbi.nlm.nih.gov/34824002
Zobrazit plný text záznamu
3
Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy
Autor: David C. Molthrop, John D. Hainsworth, Denise A. Yardley, Aleksander Jankov, Sonalee K. Shroff, Robyn R. Young, N. W. Peacock, Mythili Shastry, Amy Vander Woude, Brooke R. Daniel, Johanna Pasek, Laura M. DeBusk, Betrand Anz
Publikováno v: Breast cancer research and treatment. 180(3)
Women with residual invasive breast cancer at the primary site or axillary lymph nodes following neoadjuvant chemotherapy have a high risk of recurrence. Eribulin improves survival in patients with metastatic breast cancer who progress after anthracy
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::374ac6cee3e12185b9699633b72457ba
https://pubmed.ncbi.nlm.nih.gov/32060783
Zobrazit plný text záznamu
4
Abstract P5-14-04: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic breast cancer: Interim analysis
Autor: Andrea Silber, Robyn R. Young, N. W. Peacock, CD Webb, Laura M. DeBusk, G Chung, H. A. Burris, John D. Hainsworth, Siân Jones, Mythili Shastry, D. A. Yardley, R Midha
Publikováno v: Cancer Research. 76:P5-14
Background: The frequency of AR expression varies in the different breast cancer subtypes with 88%, 59%, and 32% expression reported in ER+, HER2+, and triple negative tumors, respectively. AR expression is associated with resistance to endocrine the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e9bd135e5ddf7992db9cdcd5a3c9c51e
https://doi.org/10.1158/1538-7445.sabcs15-p5-14-04
Zobrazit plný text záznamu
5
Abstract P1-12-04: A phase 2 study of eribulin in breast cancer not achieving a pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC)
Autor: N. W. Peacock, William N. Harwin, R Midha, Laura M. DeBusk, Brooke R. Daniel, Robyn R. Young, DC Molthrop, John D. Hainsworth, D. A. Yardley, B Anz, Mythili Shastry, R Weaver, S Shroff, Patrick S. Ward, H. A. Burris, CD Webb
Publikováno v: Cancer Research. 76:P1-12
Background: Residual breast cancer after NAC is associated with a high risk of recurrence. Little evidence supports the use of further chemotherapy in this setting. Eribulin, an inhibitor of microtubule dynamics, demonstrated a survival advantage in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3eeb6ffce78f68ac87d615b2f4951e61
https://doi.org/10.1158/1538-7445.sabcs15-p1-12-04
Zobrazit plný text záznamu
6
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score
Autor: N. W. Peacock, Mythili Shastry, Denise A. Yardley, Carl N. Yoshizawa, Amy P. Sing, Howard A. Burris, John D. Hainsworth, Rebecca Bechhold, C Hendricks
Publikováno v: Breast Cancer Research and Treatment. 154:299-308
Ixabepilone and the taxanes have similar activity in the first-line treatment of metastatic breast cancer, and ixabepilone is sometimes effective in taxane-refractory patients. We conducted a phase 2 trial to evaluate ixabepilone in combination with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9235880ba405f28a6ae0b486934ccbdd
https://doi.org/10.1007/s10549-015-3613-y
Zobrazit plný text záznamu
7
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute
Autor: N. W. Peacock, Susan Kay Morgan, Denise A. Yardley, Howard A. Burris, J. David Bass, Linda D. Bosserman, Joyce O'Shaughnessy, Victor M. Priego, William N. Harwin, John D. Hainsworth
Publikováno v: Breast Cancer Research and Treatment. 154:89-97
Amplified PI3K/Akt/mTOR signaling is common in metastatic breast cancer (MBC). The mTOR inhibitor everolimus improves progression-free survival (PFS) when added to steroidal aromatase inhibitor therapy. This randomized phase II trial compares the eff
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24086f606726d8823dfc0562d39f610c
https://doi.org/10.1007/s10549-015-3599-5
Zobrazit plný text záznamu
8
Care coordination for oral oncolytics through pharmacy integration and cycle 1-day 1 documentation
Autor: Jared Crumb, Susan A Frailley, Leah Owens, Jack L. Taylor, N. W. Peacock, Kimberly Senneke, Jeffrey Patton, Edward Arrowsmith, Aaron J. Lyss, Stacey McCullough, Carolyn J. Kelsey, Laura Kaufman
Publikováno v: Journal of Clinical Oncology. 37:260-260
260 Background: The growing number of oral oncolytic therapies (OOTs) necessitates a standardized EMR workflow that integrates pharmacy activities for dispense and patient management and standardizes cycle-1/day-1 (C1D1) documentation. Our practice
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3d25c292bfe03cfd0b5e33c2dbc25293
https://doi.org/10.1200/jco.2019.37.27_suppl.260
Zobrazit plný text záznamu
9
A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers
Autor: Douglas Flora, Peter Ruehlman, David M. Waterhouse, Cassie M. Lane, Michael McCleod, Kent C. Shih, Evan Z. Lang, Kathryn B. Alguire, Johanna C. Bendell, N. W. Peacock, Chris Earwood, Ahmed Zakari
Publikováno v: Cancer investigation. 34(5)
Purpose: To evaluate efficacy and safety of bevacizumab, pertuzumab, and octreotide depot for advanced neuroendocrine tumors.Methods: Patients received bevacizumab 15 mg/kg and pertuzumab 420 mg IV q21 days with octreotide depot 30 mg IM q28 days.Res
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a665dd3a694b22d47ead3f6e5e249420
https://pubmed.ncbi.nlm.nih.gov/27127841
Zobrazit plný text záznamu
10
Abstract P5-20-10: Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer: Preliminary Results of a Phase II Trial of the Sarah Cannon Research Institute
Autor: C Handricks, Mythili Shastry, Patrick S. Ward, N. W. Peacock, William N. Harwin, R Saez, T Chirwa, D. A. Yardley, Brooke R. Daniel, G Kannarkat
Publikováno v: Cancer Research. 72:P5-20
Background: Triple-negative breast cancer (TNBC) is a poor prognosis subtype with treatment limited to chemotherapy. Over expression of epidermal growth factor receptor (EGFR) occurs in up to 70% of TNBC providing a potential targetable receptor for
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ce3f0d5a029efd9e66d5df7ec869f64
https://doi.org/10.1158/0008-5472.sabcs12-p5-20-10
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje